Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

8.580 -0.050 (-0.58%)

Streaming Delayed Price Updated: 2:53 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government

October 04, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

A Look Into Healthcare Sector Value Stocks ↗

October 02, 2023

Via Benzinga

Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis

September 26, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

September 19, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

September 05, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Attend Upcoming Investor Conferences

August 17, 2023

From Arcturus Therapeutics

Via Business Wire

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government

August 14, 2023

From Arcturus Therapeutics

Via Business Wire

Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday ↗

August 09, 2023

U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why Shares of Arcturus Therapeutics Dropped on Tuesday ↗

August 08, 2023

The company saw revenue decline and net losses rise in the second quarter.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 08, 2023

Via Benzinga

Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 08, 2023

Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser...

Via Benzinga

Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress

August 07, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Dynavax Technologies Stock Sees Renewed Technical Strength ↗

August 07, 2023

Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.

Via Investor's Business Daily

3 Biotech Stocks to Buy Before the Breakout ↗

July 28, 2023

Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch.

Via InvestorPlace

Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023

July 24, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition ↗

July 24, 2023

William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗

July 24, 2023

Via Benzinga

Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade ↗

July 20, 2023

On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.

Via Investor's Business Daily

3 Biotech Stocks for Getting Rich in 2023 ↗

July 18, 2023

These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist.

Via InvestorPlace

Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating ↗

July 17, 2023

On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier.

Via Investor's Business Daily

UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday ↗

July 14, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Abcam Stock Earns Relative Strength Rating Upgrade ↗

June 20, 2023

A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance.

Via Investor's Business Daily

Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 14, 2023

Gainers PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement.

Via Benzinga

FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

June 06, 2023

On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.

Via Investor's Business Daily

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

June 01, 2023

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark ↗

May 25, 2023

On Thursday, Gilead Sciences stock had its Relative Strength (RS) Rating upgraded to 81, up from 78 a day earlier.

Via Investor's Business Daily

Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79 ↗

May 24, 2023

The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79.

Via Investor's Business Daily

Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark ↗

May 19, 2023

One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday.

Via Investor's Business Daily

Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

May 15, 2023

Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Via Investor's Business Daily

Analyst's Vote of Confidence: Arcturus' COVID-19 Vaccine Efforts Set to Pay Off in Japan and Beyond ↗

May 11, 2023

HC Wainwright has upgraded Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) from Neutral to Buy with

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.